Experimental combo targets Hard-to-Treat cancers

NCT ID NCT03085225

Completed Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tested the combination of two drugs—trabectedin and durvalumab—in 40 people with advanced soft-tissue sarcoma or ovarian cancer that had not responded to prior treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trabectedin and durvalumab
What this could lead to: If successful, this could point toward a new combination treatment for advanced soft-tissue sarcoma and ovarian cancer.
What could go wrong: This is a very early phase 1 trial with only 40 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CARCINOMA SOFT TISSUE SARCOMA

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69373, France
Institut Bergonié

Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.